OpenAlex 4,954 works 140 author topics
Works
4,954 works
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND: Up-to-date estimates of stroke burden and attributable risks and their trends at global, regional, and national levels are essential for evidence-based health care, prevention, and resource allocation planning. We aimed to provide such estimates for the period 1990-2021. METHODS: We estimated incidence, pr…
-
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND: Up-to-date estimates of stroke burden and attributable risks and their trends at global, regional, and national levels are essential for evidence-based health care, prevention, and resource allocation planning. We aimed to provide such estimates for the period 1990-2021. METHODS: We estimated incidence, pr…
-
OpenAlex top 1%
OpenAlex 100.0%
ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Car…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration. However, the relationship between Lp(a) levels, PCSK9 inhibition, and cardiovascular risk reduction remains undef…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND: Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse events; its effects on cardiovascular outcomes remain uncertain. METHODS: We conducted a double-blind, randomized, placebo-controlled tri…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND: Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse events; its effects on cardiovascular outcomes remain uncertain. METHODS: We conducted a double-blind, randomized, placebo-controlled tri…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND: Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events. Data from previous trials have suggested that patients receiving clopidogrel monotherapy had a lower risk of cardiovascular events than those receiving aspirin.…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND: Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events. Data from previous trials have suggested that patients receiving clopidogrel monotherapy had a lower risk of cardiovascular events than those receiving aspirin.…
-
OpenAlex top 1%
OpenAlex 99.8%
BACKGROUND: To quantify the association between effects of interventions on carotid intima-media thickness (cIMT) progression and their effects on cardiovascular disease (CVD) risk. METHODS: We systematically collated data from randomized, controlled trials. cIMT was assessed as the mean value at the common-carotid-ar…
-
OpenAlex top 1%
OpenAlex 99.6%
BACKGROUND AND PURPOSE: Plaque morphologic features have been suggested as a complement to luminal narrowing measurements for assessing the risk of stroke associated with carotid atherosclerotic disease, giving rise to the concept of "vulnerable plaque." The purpose of this study was to evaluate the ability of multide…
-
OpenAlex top 1%
OpenAlex 99.9%
No abstract yet.
-
TAXUS III Trial 2003OpenAlex top 1% OpenAlex 100.0%
BACKGROUND: The first clinical study of paclitaxel-eluting stent for de novo lesions showed promising results. We performed the TAXUS III trial to evaluate the feasibility and safety of paclitaxel-eluting stent for the treatment of in-stent restenosis (ISR). METHODS AND RESULTS: The TAXUS III trial was a single-arm, 2…
Academicians
140 academicians
- BAHATTİN HAKYEMEZ 47 author topics
- ANIL ARAT 41 author topics
- SERDAR GEYİK 39 author topics
- İSMAİL ORAN 26 author topics
- BİLGEHAN ATILGAN ACAR 25 author topics
- EROL AKGÜL 19 author topics
- MİNE HAYRİYE SORGUN 19 author topics
- MEHMET BÜLENT VATAN 16 author topics
- CANAN TOGAY IŞIKAY 15 author topics
- KIVILCIM YAVUZ 15 author topics
- BİJEN NAZLIEL 14 author topics
- CELAL ÇİNAR 14 author topics